Assignee
NEWLINK GENETICS CORP
US·14 granted patents·4 pending applications·61 citations·filing 2004–2019
Top patents by PatentIndex Score
18 records- 0192US9617272B2Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolizationNEWLINK GENETICS CORP·Filed 2014·Granted Apr 11, 2017·21 cites·43 claims
- 0290US9260434B2Fused imidazole derivatives useful as IDO inhibitorsNEWLINK GENETICS CORP·Filed 2013·Granted Feb 16, 2016·11 cites·29 claims
- 0389US10233190B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2017·Granted Mar 19, 2019·6 cites·20 claims
- 0489US7998486B2Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopesNEWLINK GENETICS CORP·Filed 2007·Granted Aug 16, 2011·5 cites·9 claims
- 0587US9388191B2Fused imidazole derivatives useful as IDO inhibitorsNEWLINK GENETICS CORP·Filed 2015·Granted Jul 12, 2016·5 cites·26 claims
- 0686US9732035B2Salts and prodrugs of 1-methyl-D-tryptophanNEWLINK GENETICS CORP·Filed 2016·Granted Aug 15, 2017·5 cites·30 claims
- 0779US9090643B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Jul 28, 2015·1 cites·4 claims
- 0879US8916169B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Dec 23, 2014·1 cites·1 claims
- 0975US10207990B2Salts and prodrugs of 1-methyl-D-tryptophanNEWLINK GENETICS CORP·Filed 2017·Granted Feb 19, 2019·1 cites·27 claims
- 1074US9850248B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2016·Granted Dec 26, 2017·1 cites·36 claims
- 1174US9174942B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2014·Granted Nov 3, 2015·2 cites·19 claims
- 1272US9981973B2Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolizationNEWLINK GENETICS CORP·Filed 2017·Granted May 29, 2018·1 cites·38 claims
- 1366US9512158B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Dec 6, 2016·0 cites·9 claims
- 1461US7078179B2Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferaseNEWLINK GENETICS CORP·Filed 2004·Granted Jul 18, 2006·1 cites·34 claims
- 1560US2019248739A1Salts and prodrugs of 1-methyl-d-tryptophanNEWLINK GENETICS CORP·Filed 2019·Application pending·0 cites
- 1653US2016089397A1Correlates of efficacy relating to tumor vaccinesNEWLINK GENETICS CORP·Filed 2014·Application pending·0 cites
- 1751US2016022826A1Carbohydrate-modified glycoproteins and uses thereofNEWLINK GENETICS CORP·Filed 2014·Application pending·0 cites
- 1845US2013289083A1IDO InhibitorsNEWLINK GENETICS CORP·Filed 2013·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →